We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Mineralys Therapeutics Inc (MLYS) USD0.0001

Sell:$12.00 Buy:$12.04 Change: $0.33 (2.82%)
NASDAQ:0.18%
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
Sell:$12.00
Buy:$12.04
Change: $0.33 (2.82%)
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
Sell:$12.00
Buy:$12.04
Change: $0.33 (2.82%)
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).

Contact details

Address:
150 N. Radnor Chester Road, Suite F200
RADNOR
19087
United States
Telephone:
+1 (302) 6587581
Website:
https://mineralystx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MLYS
ISIN:
US6031701013
Market cap:
$585.36 million
Shares in issue:
49.65 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Brian Slingsby
    Executive Chairman of the Board, Founder
  • Jon Congleton
    Chief Executive Officer, Director
  • Adam Levy
    Chief Financial Officer, Company Secretary
  • David Rodman
    Chief Medical Officer
  • Minji Kim
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.